Coherus Oncology (CHRS) Revenue Growth (3y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 122.97% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 7.94% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 4.47% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 54.05% |
| 10 | Coherus Oncology | 216.87 Mn | 49.83 Mn | 8.50 Mn | -27.60% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27.60% |
| Dec 31, 2025 | -34.49% |
| Sep 30, 2025 | -36.61% |
| Jun 30, 2025 | -44.55% |
| Mar 31, 2025 | -49.81% |
| Dec 31, 2024 | -52.76% |
| Sep 30, 2024 | -58.14% |
| Jun 30, 2024 | -51.02% |
| Mar 31, 2024 | -69.71% |
| Dec 31, 2023 | -6.06% |
| Sep 30, 2023 | -13.08% |
| Jun 30, 2023 | -24.36% |
| Mar 31, 2023 | -34.64% |
| Dec 31, 2022 | -28.46% |
| Sep 30, 2022 | -25.91% |
| Jun 30, 2022 | -10.32% |
| Mar 31, 2022 | 17.46% |
| Jun 30, 2020 | 359.33% |
| Mar 31, 2020 | 796.95% |
| Dec 31, 2019 | 427.48% |
| Sep 30, 2019 | -11.81% |
| Jun 30, 2019 | 80.99% |
| Mar 31, 2019 | 44.25% |
| Jun 30, 2017 | -34.43% |
| Mar 31, 2017 | -64.49% |
| Dec 31, 2016 | -11.85% |
| Sep 30, 2016 | 585.28% |